Safety and Efficacy Study of Pitavastatin in Patient With a Metabolic Syndrome
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
We will identify the influence of long-term treatment of Pitavastatin compared to
non-treatment control group on the metabolic syndrome by evaluation of a change of metabolic
syndrome component score. And we will additionally observe the changes of CVD risk factors
like lipid profile, abdominal fat, insulin resistance and so on.